Table 2 Steroids use in the cohort before and after WHO guideline (2nd September)
From: Real-world effectiveness of steroids in severe COVID-19: a retrospective cohort study
Overall | Before WHO | After WHO | P-value | |
|---|---|---|---|---|
n | 1100 | 366 (33.3%) | 734 (66.7%) | |
Steroids days, median [Q1,Q3] | 4.0 [0.0,7.0] | 0.0 [0.0,1.0] | 5.5 [3.0,9.0] | < 0.001 |
Steroids days > 0, n (%) | 793 (72.1) | 96 (26.2) | 697 (95.0) | < 0.001 |
Steroids days > 3, n (%) | 587 (53.4) | 63 (17.2) | 524 (71.4) | < 0.001 |
Steroids days > 10, n (%) | 134 (12.2) | 29 (7.9) | 105 (14.3) | 0.003 |
Tocilizumab days > 0, n (%) | 12 (1.1) | 12 (1.6) | 0.011 | |
Death, n (%) | 165 (15.0) | 88 (24.0) | 77 (10.5) | < 0.001 |